IONIS PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Jul 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 29, 2026
IONS$28.19-9.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except per share amounts)
| Three Months Ended · Six Months Ended | ||||
|---|---|---|---|---|
| June 30, | June 30, | |||
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Commercial revenue: | ||||
| Product sales, net | $31,139 | $19,273 | $74,094 | $25,561 |
| Royalty revenue | 75,958 | 69,952 | 134,282 | 134,117 |
| Other commercial revenue | 11,526 | 13,531 | 18,058 | 19,246 |
| Total commercial revenue | 118,623 | 102,756 | 226,434 | 178,924 |
| Research and development revenue: | ||||
| Collaborative agreement revenue | 133,137 | 336,921 | 253,797 | 381,951 |
| WAINUA joint development revenue | 16,189 | 12,372 | 33,811 | 22,785 |
| Total research and development revenue | 149,326 | 349,293 | 287,608 | 404,736 |
| Total revenue | 267,949 | 452,049 | 514,042 | 583,660 |
| Expenses: | ||||
| Cost of sales | 2,739 | 4,151 | 5,721 | 5,614 |
| Research, development and patent | 217,107 | 217,460 | 427,280 | 418,219 |
| Selling, general and administrative | 150,396 | 90,622 | 300,755 | 166,872 |
| Total operating expenses | 370,242 | 312,233 | 733,756 | 590,705 |
| Income (loss) from operations | (102,293) | 139,816 | (219,714) | (7,045) |
| Other income (expense): | ||||
| Investment income | 20,230 | 24,687 | 45,713 | 49,354 |
| Interest expense | (4,618) | (4,114) | (9,778) | (8,223) |
| Interest expense related to sale of future royalties | (17,506) | (18,648) | (34,843) | (37,470) |
| Gain (loss) on investments, net | (10,182) | (18,312) | 12,401 | (20,476) |
| Other income, net | 987 | 102 | 529 | 569 |
| Income (loss) before income tax benefit (expense) | (113,382) | 123,531 | (205,692) | (23,291) |
| Income tax benefit (expense) | (1,264) | 20 | (1,482) | (96) |
| Net income (loss) | $(114,646) | $123,551 | $(207,174) | $(23,387) |
| Basic net income (loss) per share | $(0.69) | $0.78 | $(1.25) | $(0.15) |
| Diluted net income (loss) per share | $(0.69) | $0.70 | $(1.25) | $(0.15) |
| Shares used in computing basic net income (loss) per share | 165,419 | 159,137 | 165,148 | 158,937 |
| Shares used in computing diluted net income (loss) per share | 165,419 | 182,331 | 165,148 | 158,937 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.